Empasiprubart

Phase 3Biologic

Argenx

Empasiprubart is one of 126 biologic programs targeting Myasthenia Gravis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthenia GravisActive, not recruiting

Generalized Myasthenia GravisNot yet recruiting

NeuropathyActive, not recruiting

DermatomyositisActive, not recruiting

Myasthenia GravisPhase 2

Active, not recruiting

Generalized Myasthenia GravisPhase 2

Not yet recruiting

NeuropathyPhase 3

Active, not recruiting

DermatomyositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Neuropathy

#DrugCompanyPhaseTrials

Savella

AbbVie

Phase 3

1 2

Avandia

Alnylam Pharmaceuticals

Phase 3

1 3

Vimpat

UCB

Phase 3

1 4

Asceniv

CSL Behring

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

3 6

Claritin

PPerrigo Company

Phase 3

1 7

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 8

Glutamine

Sanofi

Phase 3

2 9

Curcumin

Merck & Co.

Phase 3

1 10

Taxol

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Dermatomyositis

NCT06284954

Q1 2028

Phase 2Recruiting

Myasthenia Gravis

NCT07284420

Recruiting

Myasthenia Gravis

NCT07294170

Q2 2028

Phase 2Not yet recruiting

Generalized Myasthenia Gravis

NCT07673627

Q4 2029

Phase 3Recruiting

Neuropathy

NCT06742190

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Recruiting· Argenx logo

Argenx·Phase 3·NCT07091630·160 enrolled

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Recruiting· Argenx logo

Argenx·Phase 3·NCT06920004·218 enrolled

Myasthenia Gravis2 trials

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Recruiting· Argenx logo

Argenx·Phase 2·NCT07284420·70 enrolled

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Recruiting· Argenx logo

Argenx··NCT07294170·70 enrolled

Dermatomyositis1 trial

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Active, not recruiting· Argenx logo

Argenx·Phase 2·NCT06284954·3 enrolled

Neuropathy1 trial

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Recruiting· Argenx logo

Argenx·Phase 3·NCT06742190·115 enrolled

Generalized Myasthenia Gravis1 trial

ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Not yet recruiting· Argenx logo

Argenx·Phase 2·NCT07673627·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Empasiprubart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Empasiprubart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Empasiprubart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Argenx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Argenx

Empasiprubart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q2 2028

Q4 2029

Trials by Indication[1]

Efficacy and Safety2 trials

Myasthenia Gravis2 trials

Dermatomyositis1 trial

Neuropathy1 trial

Generalized Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News